Pimecrolimus cream 1% for treatment of vulvar lichen simplex chronicus: An open-label, preliminary trial

Gynecologic and Obstetric Investigation

Volumn 64, Issue 4, 2007, Pages 180-186

  Goldstein, Andrew T ^a,c   Parneix Spake, Anne ^b   McCormick, Calogera L ^b   Burrows, Lara J ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Center for Vulvovaginal Disorders   (United States)

Author keywords

Pimecrolimus cream 1 ; Pimecrolimus cream, efficacy and safety; Vulvar lichen simplex chronicus

Indexed keywords

PIMECROLIMUS;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CREAM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; NEURODERMATITIS; PRIORITY JOURNAL; SKIN BIOPSY; SKIN PRURITUS; VISUAL ANALOG SCALE; VULVA DISEASE;

ADMINISTRATION, CUTANEOUS; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FEMALE; HUMANS; MIDDLE AGED; NEURODERMATITIS; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME; VULVAR DISEASES;

EID: 36048959152     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000106487     Document Type: Article

References (24)

1. Lynch PJ: Lichen simplex chronicus (atopic/neurodermatitis) of the anogenital region. Dermatol Ther 2004;17:8-19.
2. Edward J, Wilkinson IKS: Atlas of Vulvar Disease. Baltimore, Williams & Wilkins, 1995.
3. Foster DC: Vulvar disease. Obstet Gynecol 2002;100:145-163.
4. Pierard GE, Pierard-Franchimont C, Ben Mosbah T, Arrese Estrada J: Adverse effects of topical corticosteroids. Acta Derm Venereol Suppl (Stockh) 1989;151:26-30, 47-52.
5. Lubach D, Rath J, Kietzmann M: Steroid-induced dermal thinning: discontinuous application of clobetasol-17-propionate ointment. Dermatology 1992;185:44-48.
6. Cherian MP, Abduljabbar M: Cushing's syndrome and adrenal suppression from percutaneous absorption of clobetasol propionate in infants. Saudi Med J 2001;22:1139-1141.
7. Hugues J, Rustin M: Corticosteroids. Clin Dermatol 1997;15:715-721.
8. Furue M, Terao H, Rikihisa W, Urabe K, Kinukawa N, Nose Y, et al: Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis. Br J Dermatol 2003;148:128-133.
9. Stuetz A, Grassberger M, Meingassner J: Pimecrolimus (Elidel®, SDZ ASM 981): preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 2001;20:233-241.
10. Hultsch T, Muller KD, Meingassner JG, Grassberger M, Schopf RE, Knop J: Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. Arch Dermatol Res 1998;290:501-507.
11. Zuberbier T, Chong SU, Grunow K, Guhl S, Walker P, Grassberger M: The ascomycin macrolactam pimecrolimus (Elidel®, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol 2001;108:275-280.
12. Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K, et al: Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002;46:495-504.
13. Warshaw E, Wohlhuter J, Drake D, Zeller S, Wenner R, Bowers S, et al: Randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. J Invest Dermatol 2005;125:A3.
14. Gribetz C, Ling M, Lebwohl M, Pariser D, Draelos Z, Gottlieb AB, et al: Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 2004;51:731-738.
15. Drake LA, Millikan LE: The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Doxepin Study Group. Arch Dermatol 1995;131:1403-1408.
16. Kaufmann R, Fölster-Holst R, Hoger P, Thaci D, Loffler H, Staab D, et al: Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants. J Allergy Clin Immunol 2004;114:1183-1188.
17. Queille-Roussel C, Paul C, Duteil L, Lefebvre MC, Rapatz G, Zagula M, et al: The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, doubleblind controlled study. Br J Dermatol 2001;144:507-513.
18. Lonsdale-Eccles AA, Velangi S: 'Topical pimecrolimus in the treatment of genital lichen planus: a prospective case series.' Br J Dermatol 2005;153:390-394.
19. Goldstein AT, Marinoff SC, Christopher K: Pimecrolimus for the treatment of vulvar lichen sclerosus in a premenarchal girl. J Pediatr Adolesc Gynecol 2004;17:35-37.
20. Goldstein AT, Marinoff SC, Christopher K: Pimecrolimus for the treatment of vulvar lichen sclerosus: a report of 4 cases. J Reprod Med 2004;49:778-780.
21. Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, et al: Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002;110:e2.
22. Meurer M, Fartasch M, Albrecht G, Vogt T, Worm M, Ruzicka T, et al: Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 2004;208:365-372.
23. Luger TA, Lahfa M, Folster-Holst R, Gulliver WP, Allen R, Molloy S, et al: Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatolog Treat 2004;15:169-178.
24. Fonacier L, Spergel J, Charlesworth EN, Weldon D, Beltrani V, Bernhisel-Broadbent J, et al: Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2005;115:1249-1253.